Evidence map›Paper›PMID 37450110›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2023

Detection of Circulating Tumor DNA in Plasma Using Targeted Sequencing.

Xue Sun, Xingyu Liu, Ying Zhao, Geng Tian, Weiwei Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Xue SunGenesis, Beijing, China.
Xingyu LiuGenesis, Beijing, China.
Ying ZhaoGenesis, Beijing, China.
Geng TianGenesis, Beijing, China. tiang@geneis.cn.
Weiwei WangGenesis, Beijing, China. wangww@geneis.cn.
Annoroad Gene Technology (China) · CNGenesis Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell-free DNA (cfDNA) is the degradation product of extracellular DNA. Circulating tumor DNA (ctDNA), as a fraction of cfDNA, comes from tumor cells and contains variations, including mutation, deletion, insertion, rearrangement, copy number variation, and methylation. Therefore, biomarkers identified in ctDNA show promising clinical applications in early diagnosis, recurrence monitoring, and conducting individualized treatment. In this chapter, we introduce experimental workflow and bioinformatic pipeline of targeted sequencing of cfDNA.

Indexed as

Cell-Free Nucleic AcidsCirculating Tumor DNABiomarkers, TumorDNA Copy Number VariationsHigh-Throughput Nucleotide SequencingMutationBiomarkers, TumorCell-Free Nucleic AcidsCirculating Tumor DNACell-free DNACirculating tumor DNAEarly diagnosisIndividualized treatmentTargeted sequencing

Identifiers

PMID37450110
OpenAlexW4384346986

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.